

Peer-to-Peer Review Checklist

You can also visit springworkstxcares.com/gomekli/hcp/resources

Scheduling a peer-to-peer review with the medical director at your patient's health plan may be useful when treatment with GOMEKLI™ (mirdametinib) is denied because of a potential misalignment with the plan's coverage policy. During the review, you will have the opportunity to explain your clinical rationale for prescribing GOMEKLI for your patient. This resource provides a checklist and relevant tips to help you prepare for and engage in a peer-to-peer discussion.

The information in this checklist does not guarantee that the health plan will provide reimbursement, and it is not intended to be a substitute for the independent medical judgment of the healthcare provider. When completing any request, it is the responsibility of the healthcare provider to adhere to the payer's specific requirements at that time.

How to Prepare for Your Peer-to-Peer Meeting

Get organized.

- Request to speak with a peer reviewer** within the same specialty
- Confirm the date and time** of the call
- Review the health plan's clinical policy** to determine if you have met all the requirements
- Gather all the documentation submitted** with the initial PA to the health plan:
 - ✓ Valid prescription for GOMEKLI
 - ✓ Letter of medical necessity
 - ✓ Copy of chart notes with details about the patient's diagnosis, current condition, laboratory values, treatment history, etc
 - ✓ Summary of your professional opinion of the patient's likely prognosis or disease progression without treatment
- If an appeal was pursued**, be sure to gather denial letter(s) received from the health plan as well as your letter of appeal in response

What to Expect During Your Peer-to-Peer Discussion

Be prepared to discuss the information below.

- Information about GOMEKLI:**
 - ✓ **GOMEKLI indication**
 - ✓ **Recommended dosage of GOMEKLI**
 - ✓ **GOMEKLI is available in 2 dosage forms:** capsules or tablets for oral suspension
 - ✓ **National Drug Code (NDC)** for form and strength prescribed
 - ✓ **Appropriate ICD-10-CM codes**
 - ✓ **Why GOMEKLI is the appropriate choice** for your patient (eg, formulation for patients with challenges swallowing capsules, only approved option for both pediatric and adult patients, safety profile, etc)
- Literature supporting your decision** to prescribe GOMEKLI:
 - ✓ **Clinical trial publication for GOMEKLI**
 - ✓ **Peer-reviewed journal articles** (For a GOMEKLI Evidence Compendium, visit springworkstxcares.com/gomekli/hcp/resources)
- Next steps:**
 - ✓ **Confirm timing and approval** and note any required follow-up steps

If the peer-to-peer discussion does not resolve the denial, an appeal should be pursued.

For a sample letter of appeal, appeals checklist, and other access resources, visit springworkstxcares.com/gomekli/hcp/resources

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

Reference: GOMEKLI. Prescribing Information. SpringWorks Therapeutics, Inc.